Re:Search Institution Members

168 Results for Members


Universidad Peruana Cayetano Heredia (UPCH) is a leading higher education institution in Lima, Peru. For 60...

The Institute of Science and Technology (INSTech) is a private scientific, cultural, and technical institution...

Established in 2013, University of Rwanda is committed to graduating the next generation of leaders who are...

The University of the Republic of Uruguay (UdelaR) is the main institution of higher education and research in...

The National Hansen's Disease Program (NHDP), part of the US Health Resources & Services Administration (HRSA)...

Anchor University Lagos (AUL) is a private, non-profit institution in Ayobo-Ipaja, Lagos, Nigeria. AUL’s...

175 Results for Collaborations


Approximately 11,000 people per month die, and approximately 450,000 people per year suffer life-altering injuries such as amputation and permanent disability, due to snakebite envenoming. Professor Nicholas Casewell, a Wellcome Trust research fellow at the Centre of Snakebite Research and Interventions (CSRI), Liverpool School of Tropical Medicine, is working on innovative approaches to discover and develop the next generation of treatments for snakebites. To support these efforts, Johnson & Johnson will be sharing its diverse compound library and a targeted set of compounds to potentially identify novel inhibitors of the toxic components of snake venom.

Johnson & Johnson is sharing its Jump-stARter library with Dr. Peter Myler at Seattle Children’s Research Institute (SCRI) for screening for leishmaniasis drug discovery. Under the umbrella of the Seattle Structural Genomics Center for Infectious Disease, SCRI is partnering with the University of Washington’s Dr. Wes Van Voorhis to carry out the screening.

Dr. Stenio Fragoso, Head of the Laboratory of Molecular Biology of Trypanosomatids at Fundação Oswaldo Cruz (Fiocruz), is interested in testing inhibitors against recombinant T. cruzi Topoisomerase II. To initiate these studies, Dr. Fragoso and investigators from Seattle Children’s Research Institute (SCRI) and the National Institute of Allergy and Infectious Diseases (NIAID)-funded Seattle Structural Genomics Center for Infectious Disease (SSGCID; contract HHSN272201700059C) are collaborating to develop constructs to express and purify T. cruzi Topoisomerase II. Once the protein is purified, it will be incorporated into an in vitro assay to identify new drugs for Chagas disease.

Merck KGaA, Darmstadt, Germany will be sharing its Mini Library of compounds with Prof. Fabrice Boyom at University of Yaoundé I for leishmaniasis and amoebiasis drug discovery. Merck KGaA, Darmstadt, Germany’s Mini Library is a collection of drug-like former Biopharma research and development compounds and their derivatives. The compounds cover a wide range of molecular targets, including enzymes, hormone and neurotransmitter receptors, transporters, and ion channels.

Dr. Edmund Ekuadzi, a former Novartis Next Generation Scientist (NGS) Program Fellow at Kwame Nkrumah University of Science and Technology (KNUST) in Ghana, has identified and purified a series of natural product extracts from Ghanaian plants for drug development purposes. Dr. Ekuadzi has shared a set of extracts with Dr. Conor Caffrey at University of California, San Diego (UCSD) to screen for human African trypanosomiasis (HAT) and schistosomiasis drug discovery.

Leishmaniasis, malaria, and human African trypanosomiasis (HAT) are among the parasitic infectious diseases that disproportionately exact a heavy toll on people living in low- and middle-income countries. Prof. Fabrice Boyom, Head of the Antimicrobial & Biocontrol Agents Unit at University of Yaoundé I, is working toward the discovery and development of novel drugs for all three diseases by targeting the parasites’ critical metabolic pathways. To support Prof. Boyom’s drug discovery research, Pfizer Inc. has agreed to provide certain potassium channel blockers.

171 Results for Assets


This invention relates to novel methods and compositions for blocking transmission of Plasmodium vivax which cause malaria. In particular, Pvs25 and Pvs28 polypeptides, variants and fusion proteins thereof, are disclosed which, when administered to a susceptible organism, induce an immune response against a 25 kD and 28 kD protein, respectively, on the surface of Plasmodium vivax zygotes and ookinetes. This immune response in the susceptible organism can block transmission of malaria. {RefNo is 1182 }
Invention provides a malaria antigen-carrier conjugate, which comprises a carrier protein and a plurality of Plasmodium antigen polypeptides. Each of the antigen polypeptides is a wild type antigen protein expressed in athe maosquito stage of Plasmodium or a derivative of the wild-type antigen protein, and each of the antigen polypeptides may be the same or different. The plurality of the Plasmodium antigen polypeptides are covalently linked to the carrier protein. The present invention further provides a vaccine against malaria, which comprises the conjugate absorbed on an aluminum adjuvant.
Mycobacterium tuberculosis is a bacteria that causes one of the most deadly and debilitating diseases of humans today. The CBER investigators developed Hybridoma 7C4.1F7 which produces a IgG2 a monoclonal antibody that recognizes the polyglycine repeat sequence, PGRS, a domain of PE_PGRS proteins from Mycobacterium. The monoclonal antibody elicited by the 7C4.1F7 hybridoma specifically identifies the PE_PGRS proteins from this bacteria that are markers for infection with TB and related pathogneic mycobacteria. Furthermore, this MAb has potential as a powerful research tool in investigating the role of PE_PGRS proteins in the immunopathogenesis of M. tuberculosis. PE_PGRS proteins belong to the PE and PE_PGRS multigene family of Mycobacterium which contains over 65 open reading frames (ORF's) with an N-terminal Proline-Glutamine amino acid motif (PE) and a C-terminal Glycine-Alanine Rich domain. PE_PGRS proteins are found on the surface of Mycobacteria, are expressed during infection, are involved as virulence factors, and are also involved in antigen diversity.
An immunologically active substantially pure peptide capable of inducing in human an immune response which is cross reactive with and protective against infection by a malaria parasite, wherein the peptide contains at least 2 consecutive repeats of a sequence Asn-X-Y-Pro wherein X is Ala or Val and Y is Asn or Asp or a sequence of the formula Thr-Glu-Trp-Z-Pro-Cys-Ser-Val-Thr-Cys-Gly-Asn-Gly wherein Z is Ser or Thr or the formula Lys-Pro-S-T-S-Lys-Leu-Lys-Gln-Pro-U-V-Gly-W-Pro wherein S is Lys or Asn, T is His or Glu, U is Gly or Asn, V is As or Glu, and W is Asn or Gln is disclosed along with DNA sequences and various other genetic materials useful in producing these peptides through biological methods.
Protective Synthetic Peptide Against Malaria And Encoding Gene; NIH reference E-519-1985 A synthetic peptide that is capable of inducing antibodies protective against malarial infection caused by Plasmodium vivax offers an important new tool for the delopment of a malarial vaccine. In order to provide this peptide in a vaccine composition, the nature of the immunodominant epitope of the surface protein of P. vivax sporozoite was identified and the gene encoding the epitope was cloned. The peptide can be administered with an adjuvant in an acceptable carrier such as a nontoxic bacterial cell or liposome.
Aegyptin and uses thereof Exposed collagen in injured blood vessels provides a substrate for platelets to adhere and aggregate initiating the first step in thrombosis, the formation of blood clots inside a blood vessel. Despite the essential role of platelets in vascular injury, excessive platelet aggregation may also result in thrombotic diseases such as stroke and heart attack. Available for licensing is a collagen binding protein, named aegyptin, which selectively inhibits collagen-platelet aggregation, but not platelet aggregation induced by other agonists. Collagen initiates recruitment of circulating platelets and triggers platelet activation. Collagen also plays a critical role in angiogenesis. Aegyptin blocks the interaction of collagen with its major ligands, von Willebrand factor, glycoprotein VI GPVI , and integrin alpha2beta1. These three ligands are of particular importance because von Willebrand factor plays a critical role in tethering platelets to collagen, GPVI is the major signaling platelet receptor, and integrin alpha2beta1 mediates platelet adhesion and contributes to activation. Since these ligands play a critical role in the early stages of thrombus formation, aegyptin represents a potentially highly effective therapeutic that can prevent and treat patients with thrombotic disease. Alternatively, aegyptin is potentially useful in conditions where collagen plays a critical role in angiogenesis or in conditions where excessive deposition of collagen plays a pathological role e.g., pancreatic carcinoma .